FOXP3 and ovarian cancer: The estimated pooled HR for all studies suggested that the risk of death was not associated with intraepithelial CD8+/FoxP3+ ratio in ovarian cancer patients (Figure 6B; HR, 0.69; 95%CI, 0.44-1.08; PHR=0.102; I2=76.6%; random effects model).